See our recent news and announcements below. If you have any questions or for media inquiries, please contact firstname.lastname@example.org for assistance or see specified media contact details within each release.
Pyramid Biosciences Announces TIME TrialTM Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors
WALTHAM, MA, April 12, 2022 - Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid’s lead oncology program PBI- 200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). [read more...]